-transparent.png){kind=logo}
Liver-targeted acetyl-coenzyme A (CoA) carboxylase (ACC) inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD) trials reveal notable secondary effects: hypertriglyceridemia and altered glucose metabolism, paradoxically with reduced hepatic steatosis. In their study, Deja et al. explored how hepatic ACC influences metabolism using different pharmacological and genetic methods, coupled with targeted metabolomics and stable isotope-based tracing techniques.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
February 1982,
Archives of biochemistry and biophysics,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
May 1980,
Journal of lipid research,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
January 1981,
Methods in enzymology,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
October 1990,
European journal of biochemistry,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
July 1966,
Proceedings of the National Academy of Sciences of the United States of America,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
June 1980,
Proceedings of the National Academy of Sciences of the United States of America,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
April 2005,
Expert opinion on therapeutic targets,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
October 2020,
Journal of medicinal chemistry,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
June 1993,
Plant molecular biology,
Armando Jesús Pérez-Díaz, and
María Ángeles Núñez-Sánchez, and
Bruno Ramos-Molina
February 2001,
Nihon rinsho. Japanese journal of clinical medicine,
